150 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
National University Of Singapore
Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
West China Hospital Of Sichuan University
Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
University Of Milan
Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Sungkyunkwan University
A sub-milligram-synthesis protocol for in vitro screening of HDAC11 inhibitors.
Nankai University
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Sichuan University
Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
Shenyang Pharmaceutical University
Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
Orchid Chemicals & Pharmaceuticals
Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.
University Of Minnesota
Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Guangzhou Institute Of Biomedicine And Health
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
University Of Minnesota
Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
University College London
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
St. Jude Children'S Research Hospital
Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties.
University Of Florida
Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
Shandong University
Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.
Istituto Ortopedico Rizzoli (Ior)
Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.
H�Pital Kirchberg
Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
R&D Sigma-Tau Industrie Farmaceutiche Riunite
Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
Shandong University
Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
TBA
Methyl effect in azumamides provides insight into histone deacetylase inhibition by macrocycles.
Technical University Of Denmark
Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
Roche Pharmaceutical Research And Early Development
ST7612AA1, a thioacetate-¿(¿-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
R&D Sigma-Tau Industrie Farmaceutiche Riunite
Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
Chinese Academy Of Sciences
Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.
Merck Research Laboratories
Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
Universit£
4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
Universit£
Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
Universit£
Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
Shandong University
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
Heinrich Heine Universit£T
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
Roche R & D Center China
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.
University Of Illinois At Chicago
Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
Kyoto Prefectural University Of Medicine
Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ¿F508-CFTR.
TBA
Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Merck Research Laboratories
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
University Of Illinois At Chicago
Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
S*Bio
Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
Universita` Degli Studi Di Siena
Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity
TBA
Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
S*Bio
Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Ortho-Biotech Oncology Research & Development
Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
Sigma-Tau Research And Development
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
R&D Sigma-Tau
Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).
Merck Research Laboratories
N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
S*Bio
Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3K?-selective template.
Anhui University Of Chinese Medicine
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Menoufia University
Design, synthesis, biochemical evaluation, radiolabeling and in vivo imaging with high affinity class-IIa histone deacetylase inhibitor for molecular imaging and targeted therapy.
Stony Brook University
Development of Alkylated Hydrazides as Highly Potent and Selective Class I Histone Deacetylase Inhibitors with T cell Modulatory Properties.
Martin-Luther University Of Halle-Wittenberg
Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer.
China Pharmaceutical University
Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
Shanghai Institute Of Pharmaceutical Industry
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
University Of Toronto Mississauga
Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
Ocean University Of China
Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
Shandong University
Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
Universit£
Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
Chinese Academy Of Medical Sciences & Peking Union Medical College
Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
China Pharmaceutical University
Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Nirma University
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
Zhengzhou University
Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
China Pharmaceutical University
Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
Southeast University
Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo.
Ocean University Of China
Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
University Of Toronto Mississauga
Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Xinxiang Medical University
Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A
Shanghaitech University
Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
China Pharmaceutical University
Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity.
West China Hospital Of Sichuan University
Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer.
Guizhou Medical University
Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
Shandong University
Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Shandong University
Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
Children'S Hospital Affiliated To Zhengzhou University
Role of Fluorination in the Histone Deacetylase 6 (HDAC6) Selectivity of Benzohydroxamate-Based Inhibitors.
Italfarmaco
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
University Of Illinois At Chicago
Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
Anhui University Of Chinese Medicine
Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
Nankai University
Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
Shenzhen Technology University
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
Shanghai Institute Of Materia Medica
Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group.
Merck
Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models.
The George Washington University
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
University Of Toronto Mississauga
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
A*Star
Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Shandong University
Discovery of Potent Small-Molecule SIRT6 Activators: Structure-Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity.
Sichuan University
Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance.
Merck
Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors.
Sichuan University
Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting.
University Of Toronto Mississauga
Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors.
Shandong University
Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
University Of Connecticut
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
Indian Csir-Central Drug Research Institute
Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy.
TBA
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
National Center For Advancing Translational Sciences
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.
University Of Toronto Mississauga
Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
Umr Cnrs 7285
Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
Northwest A&F University
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
University Of Toronto Mississauga
N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-? induced PD-L1 expression.
Taipei Medical University
Recent advances in class IIa histone deacetylases research.
Heinrich-Heine-Universit£T D£Sseldorf
Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Sichuan University And Collaborative Innovation Center Of Biotherapy
Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors.
Chinese Academy Of Sciences
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
University Of Illinois At Chicago
Discovery of Thieno[2,3-
Sichuan University And Collaborative Innovation Center Of Biotherapy
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Annji Pharmaceutical
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
Universit£
Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
National University Of Singapore
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Institute Of Biotechnology Of The Czech Academy Of Sciences
Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
TBA
Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
Shandong University
Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
Universit£
Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
Nestle Skin Health R&D
Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
Shandong University
Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11.
Forma Therapeutics
Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
Csir-Indian Institute Of Integrative Medicine
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
University Of Regensburg
3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
Taipei Medical University
Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
Universit£
Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
Ghent University
Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
National University Of Singapore
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Novartis Institutes For Biomedical Research
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
Taipei Medical University
Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
Nankai University
The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.
Soochow University
Design, synthesis, and preliminary bioactivity evaluation of N(1) -hydroxyterephthalamide derivatives with indole cap as novel histone deacetylase inhibitors.
Shandong University
PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors.
Shandong University
Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
Friedrich Miescher Institute For Biomedical Research
Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.
University Of Florida College Of Medicine